全球新型抗病毒药物市场规模、份额、趋势和成长分析报告（2026-2034年）

预计到 2034 年，新型抗病毒药物的市场规模将从 2025 年的 783.6 亿美元达到 969.2 亿美元，并预计从 2026 年到 2034 年将以 2.39% 的复合年增长率增长。

新型抗病毒药物市场正进入关键的扩张阶段，其驱动力包括新兴感染疾病、病毒变异以及分子药理学的进步。未来药物研发预计将依赖高通量筛检、人工智慧驱动的分子建模和基于结构的药物设计，以识别病毒复製和免疫逃脱的有效抑制剂。包括奈米颗粒载体和标靶生技药品在内的新一代递送系统，将在最大限度降低全身毒性的同时，优化治疗效果。

精准医疗方法将基于病毒基因型和宿主免疫特征，进一步实现抗病毒疗法的个人化，从而为每位患者量身定制治疗方案。整合人工智慧驱动的临床试验模拟、预测性药物动力学和In Silico毒性评估，将缩短研发週期，并加速产品上市速度。针对多种病毒通路联合治疗也将成为标准疗法，旨在预防抗药性并改善患者预后。

生产工艺的永续性和扩充性，以及全球监管的协调统一，将有助于在疫情爆发和大流行期间快速部署。未来的抗病毒药物市场将由创新药物模式、适应性临床通讯协定以及生物製药开发公司、研究机构和数位健康平台之间的策略合作所定义，新型抗病毒药物将成为感染疾病预防和控制的关键工具。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：新型抗病毒药物的全球市场：按类型划分

• 市场分析、洞察与预测
• 按品牌
• 学名药

第五章：新型抗病毒药物的全球市场：按药物类别划分

• 市场分析、洞察与预测
• DNA聚合酵素抑制剂
• 逆转录酶抑制剂
• 蛋白酶抑制剂
• 神经氨酸酶抑制剂
• 其他的

第六章：新型抗病毒药物的全球市场：按分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 新型抗病毒药物全球市场：依应用领域划分

• 市场分析、洞察与预测
• HIV
• 肝炎
• 疱疹
• 流感
• 其他的

第八章：全球新型抗病毒药物市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • F. Hoffmann-La Roche Ltd
  • GSK Plc
  • AbbVie Inc
  • Merck & Co. Inc
  • Johnson & Johnson Services Inc
  • Bristol-Myers Squibb Company
  • Cipla Inc
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries
  • Dr. Reddy'S Laboratories Ltd

The Novel Antiviral Drugs Market size is expected to reach USD 96.92 Billion in 2034 from USD 78.36 Billion (2025) growing at a CAGR of 2.39% during 2026-2034.

The novel antiviral drugs market is entering a pivotal expansion phase driven by emerging infectious diseases, viral mutations, and advances in molecular pharmacology. Future drug development will rely on high-throughput screening, AI-guided molecular modeling, and structure-based design to identify potent inhibitors of viral replication and immune evasion. Next-generation delivery systems-including nanoparticle carriers and targeted biologics-will optimize therapeutic efficacy while minimizing systemic toxicity.

Precision medicine approaches will further tailor antiviral therapies based on viral genotyping and host immune profiles, enabling individualized treatment regimens. Integrating AI-driven clinical trial simulations, predictive pharmacokinetics, and in silico toxicity assessments will reduce development timelines and accelerate market readiness. Combination therapies targeting multiple viral pathways will also emerge as standard practice to prevent resistance development and improve patient outcomes.

Sustainability and scalability in manufacturing processes, coupled with global regulatory harmonization, will facilitate rapid deployment during epidemic or pandemic scenarios. Future antiviral markets will be defined by innovative drug modalities, adaptive clinical protocols, and strategic collaborations between biopharmaceutical developers, research institutions, and digital health platforms-positioning novel antivirals as critical tools in proactive infectious disease management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type Scope

• Branded
• Generics

By Drug Class Scope

• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

By Distribution Channel Scope

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Application Scope

• HIV
• Hepatitis
• Herpes
• Influenza
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, GSK plc, AbbVie Inc, Merck Co Inc, Johnson Johnson Services Inc, BristolMyers Squibb Company, Cipla Inc, Aurobindo Pharma, Sun Pharmaceutical Industries, Dr Reddys Laboratories Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY TYPE SCOPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Scope
• 4.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY DRUG CLASS SCOPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class Scope
• 5.2. DNA Polymerase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Reverse Transcriptase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Protease Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Neuraminidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL SCOPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel Scope
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY APPLICATION SCOPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application Scope
• 7.2. HIV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type Scope
  • 8.2.2 By Drug Class Scope
  • 8.2.3 By Distribution Channel Scope
  • 8.2.4 By Application Scope
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type Scope
  • 8.3.2 By Drug Class Scope
  • 8.3.3 By Distribution Channel Scope
  • 8.3.4 By Application Scope
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type Scope
  • 8.4.2 By Drug Class Scope
  • 8.4.3 By Distribution Channel Scope
  • 8.4.4 By Application Scope
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type Scope
  • 8.5.2 By Drug Class Scope
  • 8.5.3 By Distribution Channel Scope
  • 8.5.4 By Application Scope
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type Scope
  • 8.6.2 By Drug Class Scope
  • 8.6.3 By Distribution Channel Scope
  • 8.6.4 By Application Scope
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL NOVEL ANTIVIRAL DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 F. Hoffmann-La Roche Ltd
  • 10.2.2 GSK Plc
  • 10.2.3 AbbVie Inc
  • 10.2.4 Merck & Co. Inc
  • 10.2.5 Johnson & Johnson Services Inc
  • 10.2.6 Bristol-Myers Squibb Company
  • 10.2.7 Cipla Inc
  • 10.2.8 Aurobindo Pharma
  • 10.2.9 Sun Pharmaceutical Industries
  • 10.2.10 Dr. Reddy'S Laboratories Ltd